Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience

Enzalutamide (ENZ) and abiraterone acetate with prednisone (AAP) represent novel hormonal therapies used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The aim of the study was to assess the long-term outcome of mCRPC patients treated with ENZ or AAP in real-life clinic...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 43; no. 1; pp. 463 - 471
Main Authors Fiala, Ondrej, Hosek, Petr, Korunkova, Hana, Hora, Milan, Kolar, Jiri, Windrichova, Jindra, Sorejs, Ondrej, Topolcan, Ondrej, Travnicek, Ivan, Sedlackova, Hana, Finek, Jindrich
Format Journal Article
LanguageEnglish
Published Greece International Institute of Anticancer Research 01.01.2023
Subjects
Abiraterone Acetate - therapeutic use
Acetic acid
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Castration
Chemotherapy
Humans
Male
Metastases
Nitriles
Patients
Prednisone
Prednisone - therapeutic use
Prostate cancer
Prostatic Neoplasms, Castration-Resistant - pathology
Retrospective Studies
Survival
Treatment Outcome
real-life practice
abiraterone acetate
Enzalutamide
castration-resistant prostate cancer
metastatic
Online AccessGet full text

Cover

More Information
Summary:Enzalutamide (ENZ) and abiraterone acetate with prednisone (AAP) represent novel hormonal therapies used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The aim of the study was to assess the long-term outcome of mCRPC patients treated with ENZ or AAP in real-life clinical practice. The outcomes of 337 mCRPC patients treated with ENZ or AAP were retrospectively analysed. Median radiographic progression-free (rPFS) and overall survival (OS) of patients treated in the first line (pre-chemotherapy) was 13.89 (95% CI=12.40-16.80) and 31.02 (95% CI=24.27-37.44) months vs. 10.97 (95% CI=8.97-14.82) and 26.57 (95% CI=15.97-33.92) months for those treated in the second line (post-chemotherapy). We found inferior survival for patients with synchronous metastases, high Gleason score (GS) and visceral metastases. The efficacy of both ENZ and AAP in mCRPC patients is herein confirmed. Synchronous metastases, high GS and visceral metastases were identified as significant adverse prognostic factors.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.16183